102 related articles for article (PubMed ID: 11259535)
1. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine.
Cichewicz DL; Haller VL; Welch SP
J Pharmacol Exp Ther; 2001 Apr; 297(1):121-7. PubMed ID: 11259535
[TBL] [Abstract][Full Text] [Related]
2. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
3. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
4. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
Cichewicz DL; Welch SP
J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
[TBL] [Abstract][Full Text] [Related]
5. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.
Williams J; Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Apr; 584(1):78-86. PubMed ID: 18313663
[TBL] [Abstract][Full Text] [Related]
6. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
Pugh G; Smith PB; Dombrowski DS; Welch SP
J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament proteins and cAMP pathway in brains of mu-, delta- or kappa-opioid receptor gene knock-out mice: effects of chronic morphine administration.
García-Sevilla JA; Ferrer-Alcón M; Martín M; Kieffer BL; Maldonado R
Neuropharmacology; 2004 Mar; 46(4):519-30. PubMed ID: 14975676
[TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
9. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
10. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
11. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
[TBL] [Abstract][Full Text] [Related]
12. The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol.
Lee MC; Smith FL; Stevens DL; Welch SP
J Pharmacol Exp Ther; 2003 May; 305(2):593-9. PubMed ID: 12606657
[TBL] [Abstract][Full Text] [Related]
13. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of mu opioid tolerance from receptor down-regulation in rat spinal cord.
Nishino K; Su YF; Wong CS; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1990 Apr; 253(1):67-72. PubMed ID: 2158554
[TBL] [Abstract][Full Text] [Related]
15. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Jul; 567(1-2):125-30. PubMed ID: 17498686
[TBL] [Abstract][Full Text] [Related]
16. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
17. Chronic Delta9-tetrahydrocannabinol treatment produces antinociceptive tolerance in mice without altering protein kinase A activity in mouse brain and spinal cord.
Dalton GD; Smith FL; Smith PA; Dewey WL
Biochem Pharmacol; 2005 Jul; 70(1):152-60. PubMed ID: 15913565
[TBL] [Abstract][Full Text] [Related]
18. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit.
Feng P; Rahim RT; Cowan A; Liu-Chen LY; Peng X; Gaughan J; Meissler JJ; Adler MW; Eisenstein TK
Eur J Pharmacol; 2006 Mar; 534(1-3):250-7. PubMed ID: 16513108
[TBL] [Abstract][Full Text] [Related]
19. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
20. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain.
Pol O; Murtra P; Caracuel L; Valverde O; Puig MM; Maldonado R
Neuropharmacology; 2006 Jan; 50(1):123-32. PubMed ID: 16360182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
